Published in Ann N Y Acad Sci on March 31, 1965
Clinical Importance of Glucose Regulation in Relapsing MS | NCT03004079
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets | NCT04550455
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev (1993) 2.12
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ (2004) 1.74
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
Spinal cord stimulation in multiple sclerosis: clinical results. J Neurol Neurosurg Psychiatry (1980) 1.56
Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48
Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A (1979) 1.47
HLA and the inheritance of multiple sclerosis: linkage analysis of 72 pedigrees. Am J Hum Genet (1980) 1.46
Stimulation of dorsal column in multiple sclerosis. Br Med J (1980) 1.38
Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A (1989) 1.36
Possible clinical outcome measures for clinical trials in patients with multiple sclerosis. Ther Adv Neurol Disord (2010) 1.34
Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol (2013) 1.34
Self reported stressful life events and exacerbations in multiple sclerosis: prospective study. BMJ (2003) 1.32
EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.29
Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol (2009) 1.27
Acute optic neuritis: prognosis for development of multiple sclerosis. J Neurol Neurosurg Psychiatry (1968) 1.24
Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci U S A (1985) 1.19
Multiple sclerosis in Coloured South Africans. J Neurol Neurosurg Psychiatry (1977) 1.19
Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol (2009) 1.18
Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J (2005) 1.17
Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res (2013) 1.16
Contribution of relapses to disability in multiple sclerosis. J Neurol (2008) 1.15
Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol (1982) 1.14
Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry (1995) 1.13
Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry (2005) 1.13
A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry (1991) 1.10
Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology (2011) 1.08
Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin (2013) 1.02
Free light chains in the cerebrospinal fluid: an indicator of recent immunological stimulation. J Neurol Neurosurg Psychiatry (1985) 1.02
Spinal cord stimulation in the United Kingdom. J Neurol Neurosurg Psychiatry (1983) 1.01
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol (1995) 1.00
Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. J Neurol Neurosurg Psychiatry (1988) 0.99
Monoclonal antibody-defined immunoregulatory cells in multiple sclerosis cerebrospinal fluid. J Clin Invest (1982) 0.98
Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2002) 0.98
Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin Exp Immunol (1983) 0.97
1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler (2000) 0.96
Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future. Expert Rev Clin Immunol (2014) 0.94
Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease. Clin Exp Immunol (1982) 0.94
Prevalence of multiple sclerosis in Saskatoon. Can Med Assoc J (1982) 0.93
Disproportionate elevation of the immunoglobulin G1 concentration in cerebrospinal fluids of patients with multiple sclerosis. Infect Immun (1979) 0.93
Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America. Ther Adv Neurol Disord (2011) 0.92
Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry (1993) 0.92
Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry (1985) 0.91
Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 0.91
Molecular mimicry revisited: gut bacteria and multiple sclerosis. J Clin Microbiol (2006) 0.91
Pregnancy and multiple sclerosis. J Neurol Neurosurg Psychiatry (1988) 0.90
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol (2009) 0.90
Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. West J Med (1994) 0.89
Morphological and biochemical findings in jejunal biopsies from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1979) 0.89
Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine detection by flow cytometry and surface marker analysis. Clin Diagn Lab Immunol (1996) 0.88
Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria. J Neurol Neurosurg Psychiatry (1995) 0.88
Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc Natl Acad Sci U S A (1992) 0.88
SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg Psychiatry (1991) 0.87
Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One (2013) 0.87
A double-blind trial of transfer factor vs placebo in multiple sclerosis patients. Clin Exp Immunol (1978) 0.86
Management of acute exacerbations in multiple sclerosis. Ann Indian Acad Neurol (2009) 0.85
Identification of three FcR-positive T cell subsets (T gamma, T mu and T gamma mu) in the cerebrospinal fluid of multiple sclerosis patients. Clin Exp Immunol (1980) 0.84
Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies. J Neurol Neurosurg Psychiatry (1975) 0.83
Dorsal column stimulation in multiple sclerosis: effects on bladder and long term findings. Br Med J (Clin Res Ed) (1983) 0.83
The diagnosis of multiple sclerosis and the clinical subtypes. Ann Indian Acad Neurol (2009) 0.83
Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. Proc Natl Acad Sci U S A (1978) 0.82
Prevalence of multiple sclerosis. Can Med Assoc J (1982) 0.82
Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry (1989) 0.82
Intrathecal synthesis of virus antibodies in multiple sclerosis patients. Infect Immun (1982) 0.82
Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int (2015) 0.81
Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis. Clin Exp Immunol (1991) 0.81
Lymphocyte adherence in multiple sclerosis: effect of aspirin. J Clin Invest (1979) 0.81
Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1994) 0.81
Verapamil-induced changes in central conduction in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1985) 0.81
Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol (1987) 0.80
Growth arrest specific gene 6 protein concentration in cerebrospinal fluid correlates with relapse severity in multiple sclerosis. Mediators Inflamm (2013) 0.80
A mechanistic, stochastic model helps understand multiple sclerosis course and pathogenesis. Int J Genomics (2013) 0.80
HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis. Clin Exp Immunol (1987) 0.80
Endogenous interleukin-6 amplifies interleukin-17 production and corticoid-resistance in peripheral T cells from patients with multiple sclerosis. Immunology (2014) 0.80
Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PLoS One (2014) 0.80
Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS One (2016) 0.79
Predictors of attack severity and duration in multiple sclerosis: a prospective study. Open Neurol J (2011) 0.79
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care (2012) 0.79
Guidelines for differential diagnosis of suspected multiple sclerosis. Nat Clin Pract Neurol (2009) 0.79
Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome. Biomed Rep (2016) 0.79
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
The prevalence of familial multiple sclerosis in saskatoon, Saskatchewan. Mult Scler Int (2014) 0.78
Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring. Can J Neurol Sci (2015) 0.78
Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group. J Neurol Neurosurg Psychiatry (1989) 0.78
Multiple sclerosis and occupational exposure to chemicals: a co-twin control study of a nationwide series of twins. Br J Ind Med (1989) 0.78
Alterations in peripheral blood mononuclear cell cytokine production in response to phytohemagglutinin in multiple sclerosis patients. Clin Diagn Lab Immunol (1995) 0.78
Familial clustering of multiple sclerosis in a northern Swedish rural district. J Neurol Neurosurg Psychiatry (1994) 0.78
Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases. J Neurol Neurosurg Psychiatry (1983) 0.78
A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients. Clin Exp Immunol (1981) 0.77
Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry (1994) 0.77
Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases. Clin Exp Immunol (1985) 0.77
Multiple sclerosis: correlation of magnetic resonance imaging with cerebrospinal fluid findings. J Neurol Neurosurg Psychiatry (1988) 0.77
Exacerbation history is associated with medication and appointment adherence in MS. J Behav Med (2011) 0.76
A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis. Int J MS Care (2011) 0.76
Platelet aggregation test with measles antigen in multiple sclerosis. Br Med J (1970) 0.76
On the evaluation of disability in multiple sclerosis. Neurology (1961) 2.87
FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS. Neurology (1965) 2.73
Myxedema neuropathy and myopathy. A clinical and pathologic study. Neurology (1961) 2.61
Minamata disease. The outbreak of a neurologic disorder in Minamata, Japan, and its relationship to the ingestion of seafood contaminated by mercuric compounds. World Neurol (1960) 2.55
A new scale for evaluating disability in multiple sclerosis. Neurology (1955) 2.53
Parkinsonism-dementia complex, an endemic disease on the island of Guam. II. Pathological features. Brain (1961) 2.41
Multiple sclerosis in Israel. Prevalence among immigrants and native inhabitants. Arch Neurol (1962) 2.40
Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota. J Chronic Dis (1958) 2.12
Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol (1962) 2.12
The frequency and geographic distribution of multiple sclerosis as indicated by mortality statistics and morbidity surveys in the United States and Canada. Am J Hyg (1952) 2.03
The incidence and prevalence of convulsive disorders in a small urban community. Epilepsia (1959) 2.03
NEUROLOGICAL SEQUELAE FOLLOWING DILANTIN OVERDOSE IN A PATIENT AND IN EXPERIMENTAL ANIMALS. Neurology (1965) 1.93
Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain (1961) 1.91
MULTIPLE SCLEROSIS IN WINNIPEG, MANITOBA: METHODOLOGICAL CONSIDERATIONS OF EPIDEMIOLOGIC SURVEY. TEN YEAR FOLLOW-UP OF A COMMUNITY WIDE STUDY, AND POPULATION RE-SURVEY. J Chronic Dis (1964) 1.86
DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY. Arch Neurol (1964) 1.81
An inherited disease similar to amyotrophic lateral sclerosis with a pattern of posterior column involvement. An intermediate form? Brain (1959) 1.74
CARCINOGENIC PROPERTIES OF NUTS FROM CYCAS CIRCINALIS L. INDIGENOUS TO GUAM. J Natl Cancer Inst (1963) 1.69
The effects of isoniazid on patients with multiple sclerosis; preliminary report. Am Rev Tuberc (1954) 1.67
Intracranial tuberculomas; a review of clinical features and treatment. Neurology (1956) 1.59
INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY. Neurology (1964) 1.57
Studies on multiple sclerosis in Winnipeg, Manitoba, and New Orleans, Louisiana. II. A controlled investigation of factors in the life history of the Winnipeg patients. Am J Hyg (1953) 1.57
Early tracheotomy in anterior poliomyelitis; importance of vital capacity determinations. J Am Med Assoc (1953) 1.56
Colles' fracture; a study of two thousand cases from the New York State Workmen's Compensation Board. J Bone Joint Surg Am (1953) 1.55
CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS. N Engl J Med (1965) 1.54
Studies on multiple sclerosis in Winnepeg, Manitoba, and New Orleans, Louisiana. I. Prevalence; comparison between the patient groups in Winnipeg and New Orleans. Am J Hyg (1953) 1.51
THE EFFECT OF GLUCAGON ON NET SPANCHNIC BALANCES OF GLUCOSE, AMINO ACID NITROGEN, UREA, KETONES, ANS OXYGEN IN MAN. J Clin Invest (1964) 1.46
Bibliography and historical note on plastic surgery of the nose. Plast Reconstr Surg (1946) (1952) 1.45
INTERFERON IN HUMAN SERUM DURING CLINICAL VIRAL INFECTIONS. Lancet (1964) 1.40
Hydrocephalus in the adult following spontaneous subarachnoid haemorrhage. Brain (1961) 1.38
Multiple sclerosis in a small New England community. N Engl J Med (1959) 1.31
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS. I. OBJECTIVES, DESIGNS, AND METHODS. Trans Am Neurol Assoc (1963) 1.29
Course of exacerbations of multiple sclerosis in hospitalized patients. AMA Arch Neurol Psychiatry (1956) 1.29
Multiple sclerosis and amyotrophic lateral sclerosis; etiologic significance of recent epidemiologic and genetic studies. N Engl J Med (1955) 1.27
Epidemiologic investigations of amyotrophic lateral sclerosis. III. A genetic interpretation of incidence and geographic distribution. Proc Staff Meet Mayo Clin (1957) 1.27
INTRACELLULAR ACID-BASE RELATIONS OF DOG BRAIN WITH REFERENCE TO THE BRAIN EXTRACELLULAR VOLUME. J Clin Invest (1964) 1.27
Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance. II. Neurology (1955) 1.27
Inclusion body encephalitis; a nonfatal case. Neurology (1956) 1.27
Certification of multiple sclerosis as a cause of death. J Am Med Assoc (1951) 1.23
Pathoanatomic changes in amyotrophic lateral sclerosis on Guam. Special reference to the occurrence of neurofibrillary changes. Arch Neurol (1961) 1.18
Relief of pain and paraesthesiae by nerve block distal to a lesion. J Neurol Neurosurg Psychiatry (1960) 1.18
Mortality in 33 countries from diseases of the nervous system. World Neurol (1962) 1.18
Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance. I. Neurology (1955) 1.17
ON THE TIME OF ONSET IN MULTIPLE SCLEROSIS. Acta Neurol Scand (1965) 1.13
INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci (1965) 1.12
Fatal toxic reaction to amphotericin B in cryptococcal meningo-encephalitis. Ann Intern Med (1960) 1.12
Peripheral neuropathy in the "collagen diseases": a case of scleroderma neuropathy. Br Med J (1960) 1.10
Multiple sclerosis; its frequency and distribution, with special reference to Denver, Colorado. Neurology (1953) 1.08
Psychiatric aspects of cord injury. Am J Psychiatry (1950) 1.07
QUANTITATIVE CLINICAL NEUROLOGICAL TESTING. I. A STUDY OF A BATTERY OF TESTS DESIGNED TO EVALUATE IN PART THE NEUROLOGICAL FUNCTION OF PATIENTS WITH MULTIPLE SCLEROSIS AND ITS USE IN A THERAPEUTIC TRIAL. Ann N Y Acad Sci (1965) 1.07
Amyotropnic lateral sclerosis in micronesia. Proc Staff Meet Mayo Clin (1954) 1.06
Neurologic diseases on the island of Guam. U S Armed Forces Med J (1954) 1.05
Abnormal protein fractions of cerebrospinal fluid demonstrated by starch gel electrophoresis. Neurology (1960) 1.02
Primary meningeal melanomas. South Med J (1953) 1.01
SOVIET SEARCH FOR VIRUSES THAT CAUSE CHRONIC NEUROLOGIC DISEASES IN THE U.S.S.R. Science (1965) 1.01
A study on traumatic lumbar punctures. Neurology (1958) 0.98
CHORIORETINOPATHY AND TOXOPLASMOSIS, AN EPIDEMIOLOGIC STUDY ON A SOUTH PACIFIC ISLAND. Arch Ophthalmol (1964) 0.97
ISOLATION OF A HIGHLY PURIFIED ENCEPHALITOGENIC PROTEIN FROM BOVINE CORD. Nature (1964) 0.96
DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE. Arch Neurol (1964) 0.95
GEOGRAPHIC AND CLIMATIC ASPECTS OF MULTIPLE SCLEROSIS; A REVIEW OF CURRENT HYPOTHESES. Am J Public Health Nations Health (1964) 0.95
Is multiple sclerosis caused by a virus? Am J Med (1952) 0.94
Fever and febrile convulsions in kittens: a clinical, electroencephalographic, and histopathologic study. J Pediatr (1954) 0.93
Multiple sclerosis. J Am Med Assoc (1950) 0.93
The frequency of intracranial and intraspinal neoplasms in the resident population of Rochester, Minnesota. J Neurosurg (1958) 0.91
Hereditary predisposition in drug-induced parkinsonism. Arch Neurol (1962) 0.91
MEASLES ANTIBODIES IN MULTIPLE SCLEROSIS. Trans Am Neurol Assoc (1963) 0.91
Normal excretion of homovanillic acid in the urine of patients with Huntington's chorea. J Neurochem (1961) 0.91
AN APPRAISAL OF POPULATION STUDIES OF MULTIPLE SCLEROSIS. Ann N Y Acad Sci (1965) 0.90
Multiple sclerosis and amyotrophic lateral sclerosis (concluded); etiologic significance of recent epidemiologic and genetic studies. N Engl J Med (1955) 0.89
Cerebrospinal-fluid culture in multiple sclerosis. N Engl J Med (1959) 0.89
Definitions of cerebral palsy and their role in epidemiologic research. Neurology (1957) 0.89
Amyotrophic lateral sclerosis among Guamanians in California. Calif Med (1957) 0.89
Neurologic manifestations of thrombotic thrombocytopenic purpura. Neurology (1958) 0.88
Thallotoxicosis. Acute manifestations and sequelae. JAMA (1963) 0.87
AN EVALUATION OF THE KURU GENETIC HYPOTHESIS. J Genet Hum (1964) 0.87
Antibody studies in rabbit encephalomyelitis induced by a water-soluble protein fraction of rabbit cord. J Exp Med (1962) 0.87
Treatment of multiple sclerosis; a review of drug therapy. J Am Med Assoc (1950) 0.87
QUANTITATIVE CLINICAL NEUROLOGICAL TESTING. II. SOME STATISTICAL CONSIDERATIONS OF A BATTERY OF TESTS. J Chronic Dis (1965) 0.86
USE OF AN ORAL CORTICOSTEROID IN THE TREATMENT OF MULTIPLE SCLEROSIS; A DOUBLE-BLIND STUDY. Arch Neurol (1965) 0.86
Effect of sodium salicylate on antibodies produced in guinea pigs. Proc Soc Exp Biol Med (1950) 0.86
Amyotrophic lateral sclerosis in the Mariana Islands. AMA Arch Neurol Psychiatry (1956) 0.86
A cutaneous disorder of connective tissue in amyotrophic lateral sclerosis. A histochemical study. Neurology (1960) 0.86
FAMILIAL INCIDENCE AND GEOGRAPHY IN MULTIPLE SCLEROSIS. Acta Neurol Scand (1965) 0.86
Studies on headache; mechanism of headache and observations on other effects induced by distention of bladder and rectum in subjects with spinal cord injuries. AMA Arch Neurol Psychiatry (1951) 0.86
FREQUENCY OF GLUCOSE-6-PHOSPATE DEHYDROGENASE DEFICIENCY, RED-GREEN COLOUR BLINDNESS AND XG-A BLOOD GROUP AMONG CHAMORROS. Nature (1964) 0.85
The frequency of glaucoma in a small urban community. Am J Ophthalmol (1957) 0.85
Acute respiratory failure in multiple sclerosis and its management. Ann Intern Med (1952) 0.85
MULTIPLE SCLEROSIS AND CEREBROSPINAL FLUID. Med Clin North Am (1963) 0.85
Study of cerebrospinal fluid proteins with paper electrophoresis. IV. Methods for concentrating dilute protein solutions. Med Bull (Ann Arbor) (1957) 0.84
Treatment of fluoroacetate poisoning in mice and dogs. J Pharmacol Exp Ther (1951) 0.84
Some observations on effect of gamma radiation on the biochemistry of the rat thymus. Proc Soc Exp Biol Med (1952) 0.84
PROCEEDINGS OF THE THIRD CONFERENCE ON THE TOXICITY OF CYCADS. INTRODUCTORY REMARKS. Fed Proc (1965) 0.84
MUSCLE FASCICULATIONS IN A HEALTHY POPULATION. Arch Neurol (1963) 0.84
Isoniazid in treatment of multiple sclerosis. J Am Med Assoc (1957) 0.83
Microsurgery as an aid to middle cerebral artery endarterectomy. J Neurosurg (1962) 0.83
Multiple sclerosis; its frequency and distribution, with special reference to San Francisco. Calif Med (1953) 0.83
Experimental cerebral infarction: the effect of dicumarol. Am J Med Sci (1957) 0.83